Hypertension最新文献

{"title":"Aspirin Improves Uterine Artery Function in Hypercholesterolemic Preeclampsia.","authors":"Amanda A de Oliveira, Floor Spaans, Murilo E Graton, Angie Stokes, Raven Kirschenman, Anita Quon, Christy-Lynn M Cooke, Sandra T Davidge","doi":"10.1161/HYPERTENSIONAHA.124.24435","DOIUrl":"10.1161/HYPERTENSIONAHA.124.24435","url":null,"abstract":"<p><strong>Background: </strong>Excessive hypercholesterolemia in pregnancy increases the risk of preeclampsia (HC-PE), though the mechanisms remain unclear. We recently showed that uterine artery function is impaired in HC-PE pregnancies via activation of the TLR4 (toll-like receptor 4)/PGHS1 (prostaglandin H synthase 1) pathway. Low-dose aspirin lowers preeclampsia risk in high-risk pregnancies by inhibiting PGHS1, but its effects in HC-PE pregnancies are not known. Moreover, oxidized low-density lipoprotein (oxLDL) levels rise in HC-PE, potentially activating TLR4 and LOX-1 (lectin-like oxLDL receptor-1; scavenger receptor linked to vascular dysfunction in preeclampsia). However, whether this occurs in HC-PE is not known.</p><p><strong>Methods: </strong>Sprague Dawley rats received a control or high-cholesterol diet (to induce HC-PE) from gestational day 6 to 20, with placebo or low-dose aspirin (1.5 mg/kg daily) given from gestational day 10 to 20. On gestational day 20, pregnancy outcomes and uterine artery function were assessed.</p><p><strong>Results: </strong>Uterine artery blood flow velocity and placental weights were higher in HC-PE placebo-treated dams versus controls, but these were reduced by low-dose aspirin. Endothelium-dependent vasodilation was impaired in the uterine arteries of the HC-PE placebo group versus controls and was corrected by low-dose aspirin. Ex vivo inhibition of TLR4, PGHS1, or LOX-1 also normalized endothelium-dependent vasodilation in the HC-PE placebo-treated dams. Exposure to oxLDL in the bath (modeling a secondary hit) further impaired endothelium-dependent vasodilation in the uterine arteries of the HC-PE placebo group, partially via TLR4 and LOX-1, which was prevented by low-dose aspirin.</p><p><strong>Conclusions: </strong>Low-dose aspirin improved uterine artery endothelial function in HC-PE pregnancies; likely by suppressing the TLR4/LOX-1/PGHS1 pathway.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"859-871"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Maternal Hypertensive Disorders.","authors":"Yan Zhao, Yue Wang, Fei Tong, Qianqian Gao, Baoxuan Li","doi":"10.1161/HYPERTENSIONAHA.124.23765","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23765","url":null,"abstract":"<p><strong>Background: </strong>Maternal hypertensive disorders during pregnancy are a worldwide health problem, particularly in the countries/regions with low sociodemographic levels. This study aimed to reveal and predict the hypertensive disorders during pregnancy-related epidemiological trends.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease 2019 study, we constructed an age-period-cohort model to assess the net drift (annual percentage changes), associated age, period, and cohort effects across global and different sociodemographic index (SDI) regions. Moreover, we analyzed attributable risk factors and future trends based on the autoregressive integrated moving average model.</p><p><strong>Results: </strong>The numbers of hypertensive disorders during pregnancy worldwide increased by 10.9% (95% uncertainty interval, 6.1-15.3) from 1990 to 2019 and only increased in the low-SDI countries. The age-standardized incidence rate declined by 23.6% (20.6, 26.9), with a global net drift of -0.8%, whereas some higher-SDI countries showed a positive net drift. After controlling for period and cohort factors, the highest incidence was observed in the 20- to 29-year age group. The period and cohort effects showed decreasing trends, whereas unfavorable period effects occurred after 2010 in high-SDI and middle-high-SDI countries. High-income North America and western sub-Saharan Africa have shown increased numbers of disability-adjusted life years due to malnutrition. The autoregressive integrated moving average model revealed downward trends in the global incidence and age-standardized incidence rate by 2030.</p><p><strong>Conclusions: </strong>Our study highlights significant regional and national variations and age differences in the burden of hypertensive disorders during pregnancy associated with SDI stratification, which will facilitate the targeting of cost-effective health policy planning, resource allocation, and women's health management by policymakers.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"e88-e101"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Left Ventricular Hypertrophy in Women With a History of Preeclampsia.","authors":"Maria G Hauge, Peter Damm, Klaus F Kofoed, Emma L R Møller, Andrea G Lopez, Anne S Ersbøll, Marianne Johansen, Per E Sigvardsen, Michael H C Pham, Jens P Goetze, Andreas Fuchs, Jørgen T Kühl, Børge G Nordestgaard, Lars V Køber, Finn Gustafsson, Jesper J Linde","doi":"10.1161/HYPERTENSIONAHA.124.23497","DOIUrl":"10.1161/HYPERTENSIONAHA.124.23497","url":null,"abstract":"<p><strong>Background: </strong>As a hypertensive disorder of pregnancy, preeclampsia is associated with increased cardiovascular morbidity and mortality later in life. Since early signs of myocardial affection could indicate a higher risk of future cardiovascular disease manifestations, we investigated whether women with prior preeclampsia have a higher prevalence of left ventricular hypertrophy compared with women from the general population and to what extent chronic hypertension affects any potential difference.</p><p><strong>Methods: </strong>In a cohort study, women aged 40 to 55 years with prior preeclampsia were compared with age- and parity-matched women from the general population. They underwent a research cardiac computed tomography, and the primary outcome was left ventricular hypertrophy, defined as a left ventricular mass index >30 g/m^2.7.</p><p><strong>Results: </strong>In 679 women with prior preeclampsia and 672 controls (median age, 47 years), we found a higher prevalence of left ventricular hypertrophy (14.0% versus 6.4%) in the preeclampsia group with an odds ratio of 1.62, 95% CI (1.07-2.46), <i>P</i>=0.024, median of 15 years (range, 0-28) after pregnancy, after adjustment for cardiovascular risk factors, including chronic hypertension. Left ventricular hypertrophy was more frequent among women with preeclampsia with (26.2% versus 15.6%) and without (5.5% versus 2.4%) chronic hypertension, and a mediation analysis showed that chronic hypertension explained 22% of the association between preeclampsia and left ventricular hypertrophy.</p><p><strong>Conclusions: </strong>Women with prior preeclampsia had a 2-fold higher prevalence of left ventricular hypertrophy compared with women from the general population, and preeclampsia was independently associated with left ventricular hypertrophy, regardless of the presence of cardiovascular risk factors, including chronic hypertension.</p><p><strong>Registration: </strong>URL: https://www.clinicalTrials.gov; Unique identifier: NCT03949829.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"774-783"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistence of a Proteomic Signature After a Hypertensive Disorder of Pregnancy.","authors":"Mark A Hlatky, Chi-Hung Shu, David K Stevenson, Gary M Shaw, Marcia L Stefanick, Heather A Boyd, Mads Melbye, Xi Du Plummer, Oshra Sedan, Ronald J Wong, Nima Aghaeepour, Virginia D Winn","doi":"10.1161/HYPERTENSIONAHA.124.24490","DOIUrl":"10.1161/HYPERTENSIONAHA.124.24490","url":null,"abstract":"<p><strong>Background: </strong>A hypertensive disorder of pregnancy is associated with a higher risk of cardiovascular disease later in life, but the potential mechanistic links are unknown.</p><p><strong>Methods: </strong>We recruited 2 groups of women, 1 during pregnancy and another at least 2 years after delivery. Cases had a hypertensive disorder of pregnancy, and controls had a normotensive pregnancy. The pregnancy cohort had study visits antepartum and postpartum; the mid-life group made a single study visit. We assayed 7288 plasma proteins, applied machine learning to identify proteomics signatures at each time point, and performed enrichment analyses to identify relevant biological pathways.</p><p><strong>Results: </strong>The pregnancy cohort (58 cases and 46 controls) had a mean age of 33.8 years, and the mid-life group (71 cases and 74 controls) had a mean age of 40.8 years. Protein levels differed significantly between cases and controls at each time point: 6233 antepartum, 189 postpartum, and 224 in mid-life. The postpartum protein signature discriminated well between cases and controls (c-index=0.78), and it also discriminated well in the independent mid-life samples (c-index=0.72). Pathway analyses identified differences in the complement and coagulation cascades that persisted across the antepartum, postpartum, and mid-life samples. The 28 proteins present in both the postpartum and mid-life signatures included 5 complement factors (3, B, H, H-related-1, and C1r-subcomponent-like) and coagulation factor IX.</p><p><strong>Conclusions: </strong>Differences in protein expression persist for years after a hypertensive disorder of pregnancy. The consistent differences in the complement and coagulation pathways may contribute to the increased risk of later life cardiovascular disease.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"872-882"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total and Free Placental Growth Factor Levels During Preeclampsia and Fetal Growth Restriction.","authors":"Amélie Jungelson, Audrey Ridoux, Marion Barthe, Diane Redel, Houria Abbas, Bassam Haddad, S Ananth Karumanchi, Edouard Lecarpentier","doi":"10.1161/HYPERTENSIONAHA.125.24736","DOIUrl":"10.1161/HYPERTENSIONAHA.125.24736","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to evaluate total circulating PlGF (placental growth factor) and free PlGF concentrations to provide insights into the mechanisms of decreased PlGF noted in preeclampsia and fetal growth restriction.</p><p><strong>Methods: </strong>We conducted a retrospective single-center study in pregnant women receiving care for suspected preeclampsia or fetal growth restriction. Serum angiogenic proteins (sFLT1 [soluble fms-like tyrosine kinase] and free PlGF) were measured on an automated platform as part of standard-of-care. Total PlGF concentrations in the serum were directly measured using a validated biochemical procedure that dissociated circulating sFLT1 and PlGF complexes. Small for gestational age (SGA) was defined by birthweight ≤10th percentile.</p><p><strong>Results: </strong>Of the 407 women studied, 155 women did not develop preeclampsia or SGA (control group), 111 women developed SGA without preeclampsia (SGA group), 71 women developed preeclampsia without SGA (preeclampsia group), and 70 developed preeclampsia and SGA (preeclampsia+SGA group). Despite reductions in free PlGF levels (229 [158-321] pg/mL), total PlGF levels were not reduced in the preeclampsia group (1020 [738-1444] pg/mL) compared with the control group (1077 [763-1595] pg/mL). In contrast, the total PlGF levels were significantly reduced in the SGA group (744 [462-1161] pg/mL; <i>P</i><0.0001) and the preeclampsia +SGA group (616 [349-917] pg/mL; <i>P</i><0.0001) compared with the control group (1077 [763-1595] pg/mL).</p><p><strong>Conclusions: </strong>Placental dysfunction associated with preeclampsia, characterized by reduced free PlGF levels but unchanged total PlGF, is driven by excessive placental production of sFLT1. Placental dysfunction associated with SGA, marked by reductions in both free and total PlGF, is mediated by decreased placental PlGF production.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"883-893"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preeclamptic Placental CD19+ B Cells Are Causal to Hypertension During Pregnancy.","authors":"Owen Thomas Herrock, Nathan Campbell, Evangeline Deer, Lorena M Amaral, Darby Whitney, Rachael Morris, Kedra Wallace, Ty Warren Turner, E Hawthorne Cleveland, Sheila Belk, George W Booz, Denise C Cornelius, Babbette LaMarca","doi":"10.1161/HYPERTENSIONAHA.124.24552","DOIUrl":"10.1161/HYPERTENSIONAHA.124.24552","url":null,"abstract":"<p><strong>Background: </strong>Patients with preeclampsia exhibit hypertension and chronic inflammation characterized by CD (cluster determinant) 4+T cells, B cells secreting AT1-AA (agonistic autoantibody against the angiotensin II type 1 receptor), inflammatory cytokines, and complement activation. Importantly, a history of COVID-19 during pregnancy is associated with an increased incidence of a preeclampsia-like phenotype and is partly mediated by CD4+T cells. We recently showed pregnant patients with a history of COVID-19 with or without preeclampsia produce AT1-AA, indicating the importance of B lymphocytes in the progression of preeclampsia and possibly of COVID-19. Therefore, we hypothesize that B cells from patients with preeclampsia with or without COVID-19 history induce the preeclampsia phenotype through AT1-AA.</p><p><strong>Methods: </strong>Placental B cells were isolated from normal pregnant, patients with preeclampsia, normotensive COVID-19 history, or preeclampsia COVID-19 history at delivery. Then, 3×10⁵ B cells were transferred intraperitoneally into pregnant athymic rats at gestational day 12. On gestational day 18, carotid catheters were inserted. On gestational day 19, mean arterial pressure was measured, and tissues were collected.</p><p><strong>Results: </strong>Preeclampsia B-cell recipients had significantly increased mean arterial pressure, AT1-AA, inflammatory cytokines, and complement activation compared with normal pregnant B-cell recipients. Recipients of B cells with COVID-19 history had markers of inflammation and hypertension but not to the level of significance as recipients of preeclampsia B cells. Inhibition of AT1-AA attenuated the hypertension that occurred in response to preeclampsia or preeclampsia B cells with COVID-19 history.</p><p><strong>Conclusions: </strong>This study demonstrates the important role of B cells in contributing to hypertension and chronic inflammation during preeclampsia with or without COVID-19 history through secretion of AT1-AA.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"894-903"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Pregnancy Hypertension.","authors":"S Ananth Karumanchi, Jane F Reckelhoff","doi":"10.1161/HYPERTENSIONAHA.125.24952","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24952","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"82 5","pages":"770-771"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Postpartum Care After a Hypertensive Disorder of Pregnancy in the United States.","authors":"Megan M McLaughlin, Neda Ghaffari, Catherine Lee, Malamo E Countouris, Phoebe Ashley, Amanda Schnell-Herringer, Divya P Mallampati, Juan M Gonzalez, Alexis L Beatty","doi":"10.1161/HYPERTENSIONAHA.124.24569","DOIUrl":"10.1161/HYPERTENSIONAHA.124.24569","url":null,"abstract":"<p><strong>Background: </strong>The postpartum period is a critical time for blood pressure monitoring and cardiovascular risk factor modification in individuals with hypertensive disorders of pregnancy (HDP), who are at increased risk for cardiovascular disease.</p><p><strong>Methods: </strong>We analyzed data from the Pregnancy Risk Assessment Monitoring System, a nationally representative US population-based survey of postpartum women with live births from 2016 to 2022. Among individuals with HDP, we evaluated the association between race, ethnicity, and other socioeconomic factors and (1) postpartum visit attendance and (2) postpartum counseling/screening.</p><p><strong>Results: </strong>Among 42 858 participants with HDP (weighted n=2 011 284), 90% reported attending a postpartum visit. Adjusting for other factors, Hispanic individuals (odds ratio, 0.75 [95% CI, 0.60-0.94]), non-Hispanic Black individuals (odds ratio, 0.75 [95% CI, 0.62-0.91]), and individuals of other or multiple races (odds ratio, 0.57 [95% CI, 0.44-0.74]) were less likely to attend a postpartum visit, compared with non-Hispanic White individuals. Individuals with lower income, lower educational attainment, and those with Medicaid or no insurance were significantly less likely to report attending a postpartum visit. Among those who reported attending a postpartum visit, only 56.3% reported receiving postpartum counseling on healthy lifestyle, 60.9% reported receiving screening for cigarette smoking, and 23.7% reported receiving testing for diabetes.</p><p><strong>Conclusions: </strong>Most individuals with HDP reported attending a postpartum visit, but there were significant disparities in postpartum visit attendance by race/ethnicity, health insurance, and socioeconomic status. In addition, many participants reported not receiving postpartum counseling or screening for cardiovascular risk factors. This represents a missed opportunity to equitably improve the long-term cardiovascular health of individuals with HDP.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"816-826"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"James R. Sowers.","authors":"Adam Whaley-Connell, Guanghong Jia, Michael A Hill, Rhian M Touyz","doi":"10.1161/HYPERTENSIONAHA.125.24610","DOIUrl":"https://doi.org/10.1161/HYPERTENSIONAHA.125.24610","url":null,"abstract":"","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":"82 5","pages":"e73-e74"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sphingosine-1-Phosphate, a Marker of Endothelial Injury and Disease Severity in Preeclampsia.","authors":"Camilla Edvinsson, Federica Piani, Frank Matthes, Lotte Vanherle, Lena Erlandsson, Anja Meissner, Stefan R Hansson","doi":"10.1161/HYPERTENSIONAHA.124.24118","DOIUrl":"10.1161/HYPERTENSIONAHA.124.24118","url":null,"abstract":"<p><strong>Background: </strong>Preeclampsia is a hypertensive pregnancy disorder marked by endothelial damage. Healthy endothelium is covered by a protective glycocalyx layer, which, when degraded, releases detectable products into the blood. Sphingosine-1-phosphate (S1P) is a cardiovascular biomarker involved in glycocalyx preservation, linked to placentation and preeclampsia development. The study aimed to test the hypothesis that plasma S1P is altered alongside glycocalyx degradation products in severe preeclampsia compared with controls.</p><p><strong>Methods: </strong>We included 121 females: 41 with severe preeclampsia requiring treatment in the intensive care unit, 40 with preeclampsia but no need of intensive care unit treatment, and 40 with normotensive pregnancies. Plasma levels of S1P and glycocalyx degradation products-hyaluronic acid, SDC-1 (syndecan-1), and HSPG2 (heparan sulfate proteoglycan-2)-were analyzed from blood samples taken within 27 hours postpartum.</p><p><strong>Results: </strong>Postpartum plasma S1P was significantly lower in the intensive care unit cohort compared with both preeclampsia controls and normotensive controls (<i>P</i><0.001). Hyaluronic acid and SDC-1 levels were elevated in the intensive care unit group versus normotensive controls (<i>P</i>=0.009 and <i>P</i>=0.023), while HSPG2 was lower (<i>P</i><0.001). Plasma S1P correlated with hyaluronic acid and blood pressure.</p><p><strong>Conclusion: </strong>Intensive care patients with severe preeclampsia have lower plasma S1P levels and higher concentrations of glycocalyx degradation products, indicating more pronounced endothelial damage. These findings suggest that S1P is associated with preeclampsia severity and may serve as a biomarker to assess vascular damage in this patient population. Further studies are needed to explore the potential role of S1P in long-term cardiovascular risk assessment for patients with preeclampsia.</p>","PeriodicalId":13042,"journal":{"name":"Hypertension","volume":" ","pages":"914-925"},"PeriodicalIF":6.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12002043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}